DeepFoqus (DeepFoqus-Accelerate)

DeepFoqus-Accelerate is an AI-powered software solution whose purpose is to enhance and transfer brain MRI images by reconstructing clinical-quality scans from undersampled data, thereby improving imaging workflow efficiency. Its methodology employs advanced AI and machine learning models, specifically convolutional neural networks, to achieve this high-fidelity reconstruction, which has undergone extensive validation confirming its intended performance.

Foqus Technologies Inc. received marketing authorization for its DeepFoqus (DeepFoqus -Accelerate) product on April 4, 2025, classifying it as a Medical Image Management And Processing System. This approval, based on substantial equivalence to existing predicate devices, permits its market release provided the company adheres to ongoing regulatory compliance including registration, device listing, manufacturing practices, and truthful labeling. DeepFoqus-Accelerate is an AI-powered standalone software solution designed to enhance and transfer brain MRI images in DICOM format, specifically reconstructing non-contrast enhanced 1.5T or 3T Siemens and GE scanner images (T1, T2, FLAIR sequences) for adult use. It leverages AI and machine learning, particularly convolutional neural networks, to reconstruct clinical-quality scans from undersampled MRI data. Extensive validation, including performance, phantom, artifact, and clinical user acceptance testing, confirmed its intended function and comparability to marketed devices.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does the DeepFoqus-Accelerate software specifically improve the diagnostic quality of undersampled MRI images compared to standard reconstruction methods?; What are the quantitative metrics used in the "extensive verification and validation activities" to assess image quality and how do they compare to conventionally acquired full-scan images?; Are there specific clinical scenarios or pathologies where the DeepFoqus-Accelerate's reconstructed images might show limitations or provide less diagnostic value compared to full-scan acquisitions?; What is the potential impact of using DeepFoqus-Accelerate on MRI scan times and patient throughput in a clinical setting, and what are the cost-benefit implications?; How adaptable is the AI model to different MRI scanner types, field strengths, or sequences not explicitly mentioned, and what is the process for updating or retraining the model?